Trial Profile
Phase II study of docetaxel and TS-1 [S 1] combination therapy for relapsed or refractory non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2009
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Oct 2006 New trial record.